CVS Health Corporation (NYSE:CVS) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• CVS Health Corporation has received a consensus rating of "Moderate Buy" from 26 analysts, with four holding ratings, twenty buying, and two indicating strong buy.
• The average 12-month price target for CVS Health is $82.57, with analysts adjusting targets based on recent performance, including Wells Fargo's increase from $84 to $103.
• The company's quarterly earnings beat expectations, reporting an EPS of $1.81 and revenue of $98.92 billion, showing an increase of 8.4% year-over-year.

Shares of CVS Health Corporation (NYSE:CVS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, twenty have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $82.5714.

A number of equities research analysts have commented on the company. Wells Fargo & Company increased their price target on CVS Health from $84.00 to $103.00 and gave the company an "overweight" rating in a research note on Tuesday, October 7th. Robert W. Baird upgraded CVS Health from a "neutral" rating to an "outperform" rating and increased their price target for the company from $71.00 to $82.00 in a research note on Thursday, August 14th. Sanford C. Bernstein increased their price target on CVS Health from $72.00 to $77.00 and gave the company a "market perform" rating in a research note on Friday, September 5th. Weiss Ratings reiterated a "hold (c)" rating on shares of CVS Health in a research note on Tuesday, October 14th. Finally, Mizuho increased their price objective on CVS Health from $76.00 to $88.00 and gave the company an "outperform" rating in a report on Thursday, October 9th.

Insider Buying and Selling at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the transaction, the director directly owned 22,156 shares of the company's stock, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.22% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CVS. Symmetry Partners LLC boosted its stake in shares of CVS Health by 2.5% during the third quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator's stock valued at $439,000 after purchasing an additional 141 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 142 shares in the last quarter. HF Advisory Group LLC boosted its stake in shares of CVS Health by 2.9% during the third quarter. HF Advisory Group LLC now owns 5,219 shares of the pharmacy operator's stock valued at $393,000 after purchasing an additional 145 shares in the last quarter. FineMark National Bank & Trust boosted its stake in shares of CVS Health by 1.7% during the second quarter. FineMark National Bank & Trust now owns 9,576 shares of the pharmacy operator's stock valued at $661,000 after purchasing an additional 157 shares in the last quarter. Finally, 1620 Investment Advisors Inc. boosted its stake in shares of CVS Health by 6.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,736 shares of the pharmacy operator's stock valued at $206,000 after purchasing an additional 157 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Down 0.1%

CVS opened at $82.47 on Tuesday. The stock has a fifty day moving average price of $74.35 and a 200-day moving average price of $68.25. CVS Health has a 12 month low of $43.56 and a 12 month high of $82.88. The firm has a market cap of $104.59 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 0.91 and a beta of 0.60. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The company had revenue of $98.92 billion during the quarter, compared to analysts' expectations of $94.87 billion. During the same period last year, the business posted $1.83 earnings per share. The firm's revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts anticipate that CVS Health will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be issued a $0.665 dividend. The ex-dividend date of this dividend is Thursday, October 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.2%. CVS Health's dividend payout ratio is currently 74.30%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.